Stock LCTX LINEAGE CELL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.14 USD +2.70% Intraday chart for Lineage Cell Therapeutics, Inc. -0.87% +4.59%
Mar. 11 Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting CI
Mar. 07 Transcript : Lineage Cell Therapeutics, Inc., Q4 2023 Earnings Call, Mar 07, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 133.3 264 413 198.9 190.7 214.9 - -
Enterprise Value (EV) 1 133.3 264 413 198.9 190.7 214.9 214.9 214.9
P/E ratio -11.1 x -12.6 x -9.42 x -7.8 x -9.08 x -10.1 x -9.19 x -9.7 x
Yield - - - - - - - -
Capitalization / Revenue 37.9 x 145 x 95.1 x 13.5 x 21.3 x 12.3 x 14.7 x 6.41 x
EV / Revenue 37.9 x 145 x 95.1 x 13.5 x 21.3 x 12.3 x 14.7 x 6.41 x
EV / EBITDA -3.73 x -10.8 x -8.54 x -9.13 x -7.93 x -8.43 x -9.27 x -21.4 x
EV / FCF - - - 308 x -6.52 x -41.3 x -8.61 x -9.07 x
FCF Yield - - - 0.32% -15.3% -2.42% -11.6% -11%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 149,794 149,991 168,558 169,976 174,987 188,534 - -
Reference price 2 0.8900 1.760 2.450 1.170 1.090 1.140 1.140 1.140
Announcement Date 3/12/20 3/11/21 3/10/22 3/9/23 3/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3.515 1.826 4.341 14.7 8.945 17.54 14.63 33.54
EBITDA 1 -35.75 -24.34 -48.34 -21.79 -24.04 -25.5 -23.18 -10.02
EBIT 1 -38.88 -26.45 -49.21 -22.52 -24.73 -21.93 -29.03 -21.42
Operating Margin -1,106% -1,448.36% -1,133.63% -153.17% -276.5% -125.06% -198.38% -63.87%
Earnings before Tax (EBT) 1 -19.23 -21.92 -43.27 -25.81 -23.28 -21.48 -25.77 -23.88
Net income 1 -11.71 -20.65 -43.02 -26.27 -21.49 -21.48 -25.77 -23.88
Net margin -333.12% -1,130.83% -990.99% -178.69% -240.2% -122.5% -176.14% -71.19%
EPS 2 -0.0800 -0.1400 -0.2600 -0.1500 -0.1200 -0.1133 -0.1240 -0.1175
Free Cash Flow 1 - - - 0.646 -29.24 -5.2 -24.95 -23.7
FCF margin - - - 4.39% -326.89% -29.65% -170.52% -70.67%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/12/20 3/11/21 3/10/22 3/9/23 3/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 0.9 2.27 1.168 5.237 4.553 2.998 1.915 2.386 3.225 1.246 2.118 1.36 1.124 1.142 13.92 0.7445
EBITDA 1 -11.89 -6.644 -28.05 -6.214 -4.055 -5.058 -6.466 -6.471 -4.854 -6.529 -6.187 -6.155 -6.275 -6.435 -6.63 -7.65
EBIT 1 - -6.843 -28.24 -6.396 -4.234 -5.251 -6.639 -6.642 -5.024 -6.705 -6.362 -7.931 -8.685 -9.271 3.827 -9.886
Operating Margin - -301.45% -2,417.64% -122.13% -92.99% -175.15% -346.68% -278.37% -155.78% -538.12% -300.38% -583.35% -772.88% -811.82% 27.5% -1,327.94%
Earnings before Tax (EBT) 1 -14.96 -8.846 -28.01 -7.093 -6.782 -5.575 -6.362 -6.207 -5.203 -7.158 -4.714 -7.342 -7.987 -8.526 2.356 -9.886
Net income 1 -14.92 -7.823 -28.99 -7.087 -6.763 -6.069 -6.354 -4.372 -5.229 -7.11 -4.775 -7.037 -7.991 -8.518 2.045 -9.87
Net margin -1,657.78% -344.63% -2,482.02% -135.33% -148.54% -202.43% -331.8% -183.24% -162.14% -570.63% -225.45% -517.63% -711.12% -745.86% 14.69% -1,325.65%
EPS 2 -0.1000 -0.0500 -0.1700 -0.0400 -0.0400 -0.0400 -0.0300 -0.0300 -0.0300 -0.0400 -0.0200 -0.0383 -0.0417 -0.0467 0.0100 -0.0500
Dividend per Share - - - - - - - - - - - - - - - -
Announcement Date 8/6/20 11/10/21 3/10/22 5/12/22 8/11/22 11/10/22 3/9/23 5/11/23 8/10/23 11/9/23 3/7/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - 0.65 -29.2 -5.2 -25 -23.7
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 0.44 - - 0.41 0.67 - - 0.5
Capex / Sales 12.52% - - 2.81% 7.53% - - 1.49%
Announcement Date 3/12/20 3/11/21 3/10/22 3/9/23 3/7/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Lineage Cell Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.14 USD
Average target price
5.2 USD
Spread / Average Target
+356.14%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
LINEAGE CELL THERAPEUTICS, INC. Stock Lineage Cell Therapeutics, Inc.
+4.59% 215M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. LCTX Stock
  4. Financials Lineage Cell Therapeutics, Inc.